The Westpoint Group has announced the divestiture of its small animal and equine veterinary practices in order to focus on production animal health and welfare.

From now, the production animal business - which includes veterinary practices providing services to pig, poultry, dairy, beef, sheep, game bird producers and small holders - will be known under the umbrella brand of Origin.

The company says that excellence and innovation in client service will continue to be the focus throughout the organisation.

Matt Dobbs, Managing Director of Origin said: "Origin is committed to supporting livestock farmers to enhance production by improving health and welfare. We have a unique group of vets, researchers, lab techs and paraprofessionals passionate about the success of UK agriculture, with other businesses committed to supporting the industry, joining us through the autumn.

"By focusing on supporting farmers, we will become a unique source of animal insight in livestock agriculture."

For more information, visit: http://www.westpointveterinarygroup.com 

The BVA, SPVS and BVNA are calling on the Government to restrict the movement of dogs from countries with high levels of diseases like Brucella canis, which are currently not widely present in the UK, and introduce mandatory pre-import testing.

In the last four years, there has been an increase in the number of identified B. canis cases in the UK, which had previously been sporadic and isolated.

Data released by the Government shows that cases have risen from three reported before 2020 to 240 in the last three years.

Most dogs were either imported, had returned from holiday overseas, or been bred with an imported dog.

In 2022, the first UK case of dog-to-human transmission was reported, highlighting the risks to those handling and treating infected dogs and raising levels of concern within veterinary teams, although the BVA says the risk is relatively low.

The BVA, SPVS and BVNA joint policy calls on the Government to :

• Restrict the movement of dogs from countries that are endemic for diseases not currently considered endemic in the UK, after carrying out a risk assessment to determine for which countries and diseases testing should be implemented.
• Introduce testing for any relevant diseases as a mandatory requirement for dogs before travel to the UK.
• Improve border controls and increase enforcement to prevent the importation of puppies and pregnant bitches.

British Veterinary Association President Anna Judson said: “Vets are seriously concerned about the lack of adequate checks for potentially zoonotic diseases entering the country via imported dogs.

"Brucella canis is not currently considered to be widespread in the UK, so a proactive approach with an emphasis on reducing the risk of this and other worrying exotic diseases being brought into the UK is crucial.

“This is important both for the health of the UK’s dogs and the humans who care for them."

https://www.bva.co.uk/take-action/our-policies/brucella-canis 

Eastcott Veterinary Referrals has found an imaginative use for the perspex safety screens introduced at the start of the pandemic: for patient restraint. 

Specifically, they're using them as a sheep race of sorts, for patient restraint during fluoroscopic examinations.

Eastcott says the transparent barrier helps to keep patients as close as possible to the practice’s mobile image intensifier, while also limiting any sudden movement. This significantly improves the quality of images taken and reduces the amount of time taken per examination.

Nicholas Taylor, referral radiographer at Eastcott came up with the idea. He said: “Unlike us humans, animals don’t understand the need to remain still and the process of getting these images was becoming quite challenging and time-consuming. Often the length of the process would make the animal anxious and we would inevitably be going in circles.

"The idea came about when we were discussing how we could replicate the x-ray process in the human world, where machines are often very close to the patient’s body.

"We had a few spare desk barriers in the hospital and decided to give it go. We were so pleased at how easy it made the entire process, reducing the amount of time per exam, improving the quality of pictures and ultimately putting the patient at ease since they can see what is going on around them.”

CVS has announced that from the start of March, it will provide free tampons and towels for all staff whilst at work. 

The company says it estimates that 75% of its staff have periods and many will find themselves caught short without a pad or tampon when they have an earlier or heavier period than expected.

This can be very embarrassing and stressful, so tampon/towel dispensing machines are being installed in the loos at every CVS veterinary practice and site in the UK.

Helen Finney, Group HR Director at CVS, said: “We want to provide dignity and peace of mind for all of the colleagues who work at CVS.

"We wouldn't expect colleagues to have to bring their own toilet paper to work.

"So those who experience periods shouldn't fear being caught short either.

"In a busy practice it can be difficult to ask a colleague if they have a tampon or towel, or to find time to go out to buy supplies.

“By providing free period products to colleagues while at work, we are seeking to help in one small but meaningful way.”

When one stops to think about this (albeit as the male editor of a veterinary website), it is something of a wonder that it has taken this long. Helen's quote about loo paper hits the nail on the head. Why do all work loos not have period products by default?

Sanofi-aventis and Merck & Co., Inc. announced today that Sanofi-aventis has exercised its option to combine Merial with Intervet/Schering-Plough, Merck's Animal Health business.

The new joint venture will be equally-owned by Merck and Sanofi-aventis. The formation of this new joint venture is subject to execution of final agreements, antitrust review in the United States, Europe and other countries, and other customary closing conditions. The completion of the transaction is expected to occur in approximately the next 12 months.

Richard T. Clark, Merck Chairman, President and Chief Executive Officer said: "Merck has been in the animal health business for well over six decades and through this new joint venture, we will bolster our diverse portfolio and create a new global competitor poised for growth.

"This new joint venture delivers on Merck's commitment to customer focus by creating one of the broadest portfolios of animal health products and services in pharmaceuticals and biologics for millions of customers who include farmers, veterinarians and pet owners. The planned joint venture will have an attractive geographical network of global technology and  expertise to provide health solutions based on customers' needs, which often vary regionally."

The worldwide animal health market reached $19 billion in 2008. Products for companion animals accounted for 40 percent of total sales while products for production animals accounted for the remaining 60 percent of total sales. This market is expected to grow at around 5 percent per year over the next 5 years, driven by a growing demand for animal proteins, as well as a strong consumer needs for companion animal health care.

The companies said that both Merial and Intervet/Schering-Plough will continue to operate independently until the closing of the transaction.

The Equine Veterinary Journal has published a free special collection of new research on Equine Grass Sickness this month.

Four separate studies are included in the collection, reporting novel risk factors for the disease, identifying key differences between EGS and botulism (questioning the hypothesis that EGS is caused by neurotoxins from Clostridium botulinum), reporting a novel diagnostic technique and showing the value of monitoring weight loss to help predict whether individual horses with chronic EGS are likely to survive.

The publishers say that despite more than 100 years of research, supported predominantly by the The Moredun Foundation Equine Grass Sickness Fund (www.grasssickness.org.uk), the cause of EGS remains unknown. Since it almost exclusively affects grazing horses, a pasture derived neurotoxin is implicated. EGS causes gut paralysis as a result of damage to parts of the nervous system that control involuntary functions. Acute and sub-acute EGS is invariably fatal while around 55% of chronic cases can survive and return to a useful working life. The UK has the highest incidence of EGS in the world; indeed it is estimated that the disease kills between 1 and 2% of horses in the United Kingdom annually. Cases are more common in spring.

In terms of risk factors, the study ‘Equine grass sickness in Scotland: A case-control study of environmental geochemical risk factors’ suggests that the high incidence of the disease in Eastern Scotland may be partly associated with the particular composition of macro and trace elements in the soil in the fields on which horses graze. Further work is required to determine whether interventions to alter concentrations of particular elements in soil could potentially reduce the risk of EGS.¹

A second study identified key differences between EGS and botulism, which questions the currently favoured hypothesis that EGS is caused by neurotoxins from Clostridium botulinum, a bacterium which commonly inhabits soil. The study ‘Equine grass sickness, but not botulism, causes autonomic and enteric neurodegeneration and increases soluble N-ethylmaleimide-sensitive factor attachment receptor protein expression within neuronal perikarya’ suggests that EGS is unlikely to be caused by neurotoxins from this bacterium and concludes that further investigation of an alternative cause for EGS is needed.²

While the majority of horses with EGS can be readily diagnosed by experienced veterinary surgeons, some cases present a diagnostic challenge. Indeed the only way to definitively diagnose the disease in a live horse is to demonstrate the characteristic degeneration of nerves within biopsies of the intestine. Unfortunately these biopsies can only be collected by performing abdominal surgery under general anaesthesia. In the study ‘Neuronal chromatolysis in the subgemmal plexus of gustatory papillae in horses with grass sickness’ characteristic degeneration of nerves was identified in small biopsies collected from tongues of EGS horses during post mortem examination. Examination of these biopsies accurately differentiated control horses from EGS cases. While further validation of this technique is required, it could potentially provide a relatively non-invasive method of confirming the diagnosis in a live horse.³

While around 55% of horses with chronic EGS survive, objective criteria for predicting survival of these cases are currently lacking. The study ‘Bodyweight change aids prediction of survival in chronic equine grass sickness’ reported that non-survivors had greater rate and magnitude of bodyweight loss than survivors. Survival prediction curves were published to allow veterinary surgeons and horse owners to use body weight data to help determine whether an individual horse with chronic EGS was likely to survive or die.⁴

Professor Bruce McGorum, Head of the Equine Section at the Royal (Dick) School of Veterinary Studies & Roslin Institute in Edinburgh, has been leading much of the research. He said: "Given that our recent research suggests that EGS is unlikely to be caused by neurotoxins from Clostridium botulinum we are now moving on to determine whether EGS is caused by ingestion of mycotoxins produced by pasture fungi. We are very pleased that The Horse Trust (www.horsetrust.org.uk) has provided funding for this three-year investigation."

Professor Celia Marr, Editor of the Equine Veterinary Journal said: “While the cause of equine grass sickness continues to evade us, these papers present an optimistic step in the right direction for the eventual prevention of this dreadful disease. It is only with the support of the Moredun Foundation Equine Grass Sickness Fund and more recently that of The Horse Trust that our world-leading veterinary researchers are able to continue to unravel the mystery.”

The EVJ equine grass sickness collection can be downloaded at http://bit.ly/2dC7Drr

References

1. Equine grass sickness in Scotland: A case-control study of environmental geochemical risk factors C. E. Wylie, D. J. Shaw, F. M. Fordyce, A. Lilly, R. S. Pirie, B. C. McGorum
2. Equine grass sickness, but not botulism, causes autonomic and enteric neurodegeneration and increases soluble N-ethylmaleimide-sensitive factor attachment receptor protein expression within neuronal perikarya B. C. McGorum, S. Scholes, E. M. Milne, S. L. Eaton, T. M. Wishart, R. Poxton, S. Moss, U. Wernery, T. Davey, J. B. Harris, R. S. Pirie
3. Neuronal chromatolysis in the subgemmal plexus of gustatory papillae in horses with grass sickness B. C. McGorum, R. S. Pirie, D. Shaw, N. Macintyre, A. Cox
4. Bodyweight change aids prediction of survival in chronic equine grass sickness R. C. Jago, I. Handel, C. N. Hahn, R. S. Pirie, J. A. Keen, B. E. Waggett, B. C. McGorum

Dechra Veterinary Products has produced a pair of presentations, aimed at pet owners, for vets to use in receptions and at client events. The presentations cover canine hyperadrenocorticism, aka Cushing's syndrome, and feline hyperthyroidism.  

Matthew Olsen, Product Manager, said: "We are committed to delivering a wide range of support materials and tools to enable vets to provide help and information to their customers.  We have developed an owners' booklet on both Cushing's and hyperthyroidism and have now backed this up with PowerPoint presentations for vets to use with their clients.  Some veterinary practices are using technology to revolutionise waiting room displays and we have responded to their needs by producing a presentation they can use on their waiting room information screens."

The Dechra Hyperadrenocorticism presentation covers what Cushing's is, what causes it and what owners need to look for. The presentation also explains the treatment options available. The Hyperthyroidism presentation details what the condition is and gives information on the thyroid gland. It highlights what cat owners need to look out for, including weight loss in spite of a ravenous appetite, increased fluid intake and increased restlessness.  The presentation also advises people of what to do should they suspect their cat has hyperthyroidism and what the treatment options are.       

Garden Lodge Veterinary Clinic in Holywood, County Down, has used the Hyperthyroidism presentation at both its practices. Partner Tom Fitzsimons said: "We have used the presentation on our reception information screens.  The presentation has raised owners' awareness and shown them it is a manageable condition.  It's led to an increase in the number of cats we are now testing for Hyperthyrodism.  We also plan to run the Cushing's presentation in the future." 

Veterinary Practices interested in getting hold of a free copy of the Hyperthyrodism and Hyperadrenocorticism presentations should contact Matthew Olsen at Dechra on 01743 441 632 or email matthew.olsen@dechra.com

Boehringer Ingelheim has launched a smaller, 12ml bottle of Senvelgo (velagliflozin), its treatment for feline diabetes, in Great Britain, Northern Ireland and Ireland.

This allows patients to try the drug at lower cost, before progressing to the 30ml bottle for ongoing treatment.

Samantha Taylor, RCVS Recognised Specialist in Feline Medicine said: “It’s great we now have the option to prescribe the smaller 12ML bottle for starting cats on Senvelgo, as it means we don’t have to worry about wasting a 30ml bottle if it becomes evident that the cat requires insulin in the first couple of weeks.”

https://senvelgo.co.uk 

In light of the currently worsening situation across the UK, the Welsh Government’s decision to impose a further lockdown, and the potential for tighter lockdown restrictions elsewhere in the country, the RCVS has produced two flow charts and two sets of temporary guidance on remote prescribing, to reflect the main two types of government restrictions a practice may be working under.

The two sets of guidance cover:

1. Circuit-break’ or ‘Fire-break’ lockdown conditions: FAQ2a and FAQ4a
   A ‘new’ flowchart which broadly represents a return to the College’s original guidance in April to undertake essential and emergency work only and with a temporary option to remote prescribe POM-Vs at an earlier stage, subject to certain conditions.
2. Tier 1, 2, or 3 restrictions: FAQ2b and FAQ4b
   The current flowchart which incorporates all of Council’s recent changes, including an expectation that a veterinary surgeon should first endeavour to bring an animal under their care before considering prescribing POM-Vs remotely, subject to certain conditions.

RCVS President Dr Mandisa Green said: “I would like to reassure my colleagues once again that we understand the extreme challenges and difficult decisions they are facing.

"The College has no interest in taking anyone to task for considered professional judgement, providing they act reasonably in the circumstances, can justify their actions and take reasonable notes.

"Sadly, we’re seeing the pandemic situation deteriorating again in the UK, but to varying degrees across the country. This presents a significant challenge in ensuring our guidance is clear and straightforward, while remaining relevant to as many people as possible.

"We sincerely hope this new guidance achieves that aim and supports veterinary professionals working to uphold animal health and welfare, while maintaining the safety of their teams and clients."

For more information, visit: https://www.rcvs.org.uk/setting-standards/advice-and-guidance/coronavirus-covid-19/ 

Zoetis Business Consulting has announced the launch of Profitsolver, a software tool designed to boost practice profits.

The software has already been rolled out in the US, where Zoetis says that it has delivered an average of £103,000 extra profit to veterinary practices within a year.

Profitsolver uses the practice's actual data - not benchmarks or accepted norms - to enable the practice to manage costs, set prices and gain return on investments. By using an activity-based costing model and using a variety of data such as practice costs, which staff perform which part of the procedure, how long the procedure takes and what equipment and materials are used, Profitsolver calculates the correct pricing to both cover costs and deliver a predetermined profit margin.

Zoetis says that Profitsolver helps practices to understand how the overall practice profit is being generated. For instance, for price sensitive procedures such as vaccination, the practice can match their prices with the competition, but maintain their profit margin by increasing the price for other clinical services.

Nick Steele, national consulting manager at Zoetis said: "Veterinary practices have no standard method for pricing their services and they are often unable to determine which services make money and which don't. This hampers the practice's ability to accurately value the business and, as a result, profit levels tend to be low for many practices. Profitsolver can turn this situation around and already has a very successful track record in the US."

Zoetis piloted the UK version of Profitsolver with John Goulding at St Georges Veterinary Group. He said: "By and large the veterinary profession still relies on the mark-up of medicines where profits are concerned. Even practices that have made a concerted effort to move away from this type of pricing structure are still making their money from the sale of medicines rather than from vets' fees. For years I have wanted to know exactly how to price our services and this new Profitsolver software does just that.

"Most costs have an element of staff time, an element of fixed assets or equipment and an element of disposable items. Profitsolver takes all of these into account, adds the predetermined profit margin and produces an accurate pricing structure for each procedure undertaken within the practice.

"It's important to take the time at the start to put accurate data in from the practice's latest set of accounts and the Zoetis business consultant will guide practices through this to make the initial set up as easy as possible. For instance, for major pieces of equipment such as X-ray machines, you have to work out how many times a year you are likely to use them.

"By using Profitsolver, we worked out that if we do exactly the same amount of work as last year we can increase our bottom line by at least £200,000 for our 18 vet practice. Since last November, when we installed Profitsolver, we have completely changed our pricing structure moving away from focusing on medicines and the size of the animal to rethink how we charge our clinical care.

"An unexpected benefit is that Profitsolver has made me much more confident about the prices we charge to clients as it is all broken down, so we can see exactly how the invoice is made up. I would be at a loss without it now."

For more information about Profitsolver, contact your Zoetis account manager.

Petplan has launched what it says is the biggest advertising campaign in its 36-year history.

The company won't reveal what it's spending on the campaign, but its built around a TV advert (below) being shown on all the major channels throughout January, so certainly a bob or two. The ad features 45 different breeds of cats, dogs and rabbits - representing some of the breeds Petplan has insured over the years.

Simon Masding, head of sales and partnerships at Petplan said: "As the UK market leader, it is imperative pet owners recognise and understand who we are and what we stand for. We want to help our partners educate pet owners not only why pet insurance is so important, but explain why they should choose Petplan over any other provider. In 36 years, there's not an illness or accident that we haven't seen and our new advert dramatises in a charming way the depth and breadth of our breed and claims experience".

As part of the campaign, Petplan is running a 'Guess the Breed' game: correctly identify 10 of the breeds featured and be in with the chance to win a Petplan gilet. To enter, visit www.petplanvet.co.uk

The British Veterinary Association has welcomed the European Parliament vote to improve the labelling of food, including new country of origin labelling and a requirement to label meat from animals slaughtered without stunning (according to certain religious traditions).

The BVA believes that all animals should be stunned before slaughter, for welfare reasons. However, as long as slaughter without stunning is permitted the BVA has argued for any meat from this source to be clearly labelled to enable all consumers to fully understand the choice they are making when buying such products.

Meat from slaughter without stunning currently enters the mainstream food chain without being labelled as such, leaving consumers unaware.

The European Parliament also voted to extend country of origin labelling to all meat, poultry, dairy products and other single-ingredient products as well as all meat, poultry and fish when used as an ingredient in processed food. Importantly, meat labels should indicate where the animal was born, reared and slaughtered.

The UK enjoys some of the highest animal welfare standards in the production of food and the improved country of origin labelling will allow consumers to make a more informed choice.

The BVA is calling for one clear EU welfare label that takes into account the welfare of animals use in food production from birth to slaughter, including the production system, transport and method of slaughter.

Professor Bill Reilly, President of the BVA, said: "This is a huge step forward in improving the welfare of animals at slaughter. The more consumers understand these issues, the more consumer power can make a difference.

"The BVA has argued for some time for meat from animals slaughtered without the more-humane method of stunning should be labelled as such and we are delighted that the European Parliament supports this view.

"However, there are many issues associated with the welfare of animals in food production and the BVA would like to see the development of a clear welfare label that consumers recognise as a mark of higher animal welfare.

"Currently there are too many different labels that mean different things, which can be confusing for shoppers. One higher welfare label would go a long way to improving consumer choice and animal welfare."

The PDSA is asking vets to take part in the PAW Report, its annual research into pet wellbeing. 

The 2023 PAW Report will assess how lifestyle changes caused by the COVID-19 pandemic and the cost of living crisis have affected the nation’s pets.

The survey, which is open to vets, veterinary nurses and students, closes on 10th February 2023.

Entrants will be in with a chance of winning a £100 One4all voucher, accepted in over 130 high street stores.

Rebecca Ashman, PDSA’s Veterinary Engagement and Communication Manager said: “The PAW Report provides invaluable insight into key areas of pet wellbeing in the UK.

"Lifestyles had to adapt and change through the pandemic, and now as we navigate a cost of living crisis, this research is more vital than ever before.” 

Rebecca added: “It takes less than 15 minutes to complete the survey, and by taking part you’ll be helping us maintain an accurate picture of the biggest welfare issues facing pets in the UK today.”

Survey: https://start.yougov.com/refer/vz7hC0lZ0d10nG